5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
30 August 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2024 PBAC ...
19 July 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2024 ...
19 July 2024 - The utilisation analysis public release documents from the June 2024 DUSC meeting are now available. ...
19 July 2024 - The outcome statement from the June 2024 DUSC meeting is now available. ...
10 July 2024 - The Health Technology Assessment (HTA) Policy and Methods Review concluded on 4 May 2024. The HTA ...
5 July 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2024 PBAC ...
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common ...
30 May 2024 - EMA’s annual report 2023 published today details the Agency’s contributions to public and animal health in the ...
30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds ...
5 April 2024 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2023 PBAC ...
26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
22 March 2024 - The Outcome Statement from the February 2024 DUSC meeting is now available. ...
15 March 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2023 PBAC ...
1 March 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2023 PBAC ...